Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0O7QQ
|
||||
Former ID |
DNCL002471
|
||||
Drug Name |
BIIB 022
|
||||
Indication | Hepatocellular carcinoma; Non-small cell lung cancer [ICD9: 155; ICD10:C22.0, C33-C34] | Phase 1 | [548652] | ||
Company |
Biogen Idec
|
||||
Target and Pathway | |||||
Target(s) | Insulin-like growth factor I receptor | Target Info | Antagonist | [532644] | |
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
HIF-1 signaling pathway | |||||
FoxO signaling pathway | |||||
Oocyte meiosis | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
AMPK signaling pathway | |||||
Focal adhesion | |||||
Adherens junction | |||||
Signaling pathways regulating pluripotency of stem cells | |||||
Long-term depression | |||||
Ovarian steroidogenesis | |||||
Progesterone-mediated oocyte maturation | |||||
Pathways in cancer | |||||
Transcriptional misregulation in cancer | |||||
Proteoglycans in cancer | |||||
Glioma | |||||
Prostate cancer | |||||
Melanoma | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.